Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC) (FIONA)

AstraZeneca

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT00880711

NIS-OAT-FAS-2009/1

Details and patient eligibility

About

The purpose is to collect real life data on the use of fulvestrant in normal clinical practice in Austria and document the clinical benefit of fulvestrant treatment.

Enrollment: 57 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer
• Ability to read and write and complete questionnaires
• Provision of written informed consent
• Patients who already received a prescription for fulvestrant

Exclusion criteria

• A subject who does not fulfil all the above mentioned inclusion criteria is not allowed to participate in this NIS

Trial design

57 participants in 1 patient group

1

Description:

Patient with advanced BC, already receiving Faslodex therapy